New scan could spot hidden prostate cancer spread

NCT ID NCT01543659

Completed Diagnosis Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new type of PET scan using a radioactive tracer called 89Zr-DFO-huJ591 to find prostate cancer that has spread to other parts of the body. 77 men with metastatic prostate cancer received the experimental scan, and some also had standard scans and biopsies for comparison. The goal was to see if the new scan is safe and accurate at detecting cancer sites, especially in bones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 89Zr-DFO-huJ591 (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a more accurate way to detect metastatic prostate cancer, helping doctors choose better treatments.
What could go wrong: This is an early-phase study with only 77 participants. The new scan may not be more accurate than existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.